Avadel Pharmaceuticals plc - ADR logo

AVDL

Avadel Pharmaceuticals plc - ADR

$6.72

Earnings Summary

Revenue
$0Mn
Net Profits
$-26.42Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Avadel Pharmaceuticals plc - ADR’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Avadel Pharmaceuticals plc - ADR has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Avadel Pharmaceuticals plc - ADR’s net profit fell -96.53% since last year same period to $-26.42Mn in the Q1 2022. On a quarterly growth basis, Avadel Pharmaceuticals plc - ADR has generated -18.49% fall in its net profits since last 3-months.

Net Profit Margins:

Avadel Pharmaceuticals plc - ADR’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Avadel Pharmaceuticals plc - ADR has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Avadel Pharmaceuticals plc - ADR post its latest quarter earnings

EPS Estimate Current Quarter
-0.43
EPS Estimate Current Year
-0.43

Highlights

EPS Estimate Current Quarter:

Avadel Pharmaceuticals plc - ADR’s earning per share (EPS) estimates for the current quarter stand at -0.43 - a -4.88% fall from last quarter’s estimates.

EPS Estimate Current Year:

Avadel Pharmaceuticals plc - ADR’s earning per share (EPS) estimates for the current year stand at -0.43.

Key Ratios

Key ratios of the Avadel Pharmaceuticals plc - ADR post its Q1 2022 earnings

Earning Per Share (EPS)
-0.45
Return on Assets (ROA)
-0.29
Return on Equity (ROE)
-2.32
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Avadel Pharmaceuticals plc - ADR’s earning per share (EPS) fell -95.65% since last year same period to -0.45 in the Q1 2022. This indicates that the Avadel Pharmaceuticals plc - ADR has generated -95.65% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Avadel Pharmaceuticals plc - ADR’s return on assets (ROA) stands at -0.29.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Avadel Pharmaceuticals plc - ADR’s return on equity (ROE) stands at -2.32.

Dividend Per Share (DPS):

Avadel Pharmaceuticals plc - ADR declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.43
-0.45
-4.65%

Company Information

Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.

Organisation
Avadel Pharmaceuticals plc - ADR
Headquarters
Dublin, Dublin, Ireland
Employees
2.02K
Industry
Health Technology
CEO
Gregory Divis